MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. (Nasdaq: INKT) is a clinical-stage biotechnology company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its lead candidate, agenT-797, is a native iNKT therapy being studied in solid tumors, severe pneumonia and… From the company’s description.
In fiscal 2025, MiNK Therapeutics, Inc. reported a net loss of $12.49M. Operations used $5.93M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MiNK Therapeutics, Inc. does
In the company’s own words
MiNK Therapeutics, Inc. (Nasdaq: INKT) is a clinical-stage biotechnology company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its lead candidate, agenT-797, is a native iNKT therapy being studied in solid tumors, severe pneumonia and hypoxemic respiratory failure, and graft-versus-host disease. The company is also developing engineered iNKT candidates, including MiNK-215, a FAP-targeted CAR-iNKT program, and MiNK-413, a BCMA-targeted CAR-iNKT program, alongside T-cell receptor and iNKT engager technologies. Its proprietary neoantigen library supports development of personalized T-cell receptor therapies, and its CARDIS platform is used in cell-engineering research. MiNK operates a cGMP manufacturing suite and produces its native iNKT cell programs in-house. Its pipeline includes wholly owned or exclusively licensed assets, while collaborations with Agenus and other partners support combination therapy and technology development. MiNK reports one business segment and had no commercial product revenue described among its activities. Its website is https://minktherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1840229
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MiNK Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MiNK Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MiNK Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MiNK Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MiNK Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”